Losartan Switching Protocols: How to Switch From or To Other Drugs in Class

How Losartan Works and Why It Matters for Switching

Losartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing the vasoconstrictive, aldosterone-releasing, and sodium-retaining effects of angiotensin II. The liver converts losartan (via CYP2C9 and CYP3A4) into its active metabolite EXP3174, which is 10 to 40 times more potent at the AT1 receptor than the parent compound 1.

This prodrug pharmacology is the first thing a clinician should consider when planning a switch. Patients who are CYP2C9 poor metabolizers (roughly 1 to 3% of Caucasians, up to 8% of some African populations) generate less EXP3174 and may respond poorly to losartan while responding normally to an ARB that does not require hepatic activation, such as valsartan or azilsartan 2. If blood pressure remains uncontrolled at losartan 100 mg and adherence is confirmed, CYP2C9 polymorphism is a reasonable clinical suspicion.

All seven FDA-approved ARBs share the same AT1 receptor target. Their differences lie in binding affinity, half-life, volume of distribution, and metabolic pathway. Losartan and EXP3174 together provide the shortest effective half-life of any ARB (6 to 9 hours combined), compared to telmisartan at 24 hours and olmesartan at 13 hours 3. That shorter duration explains why some patients on losartan experience an end-of-dose blood pressure rise that resolves when switched to a longer-acting agent.

ARB Dose Equivalency Table for Switching

The approximate milligram-equivalent conversions below are derived from a 2011 meta-analysis of 46 randomized trials (N=13,451) that compared ARBs at their labeled doses for systolic blood pressure reduction 4. These are starting-point conversions, not exact matches. Individual titration is still required.

| Losartan | Valsartan | Candesartan | Irbesartan | Telmisartan | Olmesartan | Azilsartan | |----------|-----------|-------------|------------|-------------|------------|------------| | 25 mg | 40 mg | 4 mg | 75 mg | 20 mg | 10 mg | 20 mg | | 50 mg | 80 mg | 8 mg | 150 mg | 40 mg | 20 mg | 40 mg | | 100 mg | 160 mg | 16 mg | 300 mg | 80 mg | 40 mg | 80 mg |

A direct switch at the equivalent dose is the standard approach. The 2017 ACC/AHA Hypertension Guideline does not require a titration-up period when converting within the ARB class, though it does recommend a blood pressure recheck within 1 month 5. Renal function and serum potassium should be rechecked at 1 to 2 weeks, especially in patients with an eGFR <60 mL/min/1.73 m² or baseline potassium above 4.5 mEq/L.

Switching Losartan to a More Potent ARB

Losartan ranks at the bottom of the ARB class for ambulatory blood pressure reduction. A network meta-analysis published in the Journal of Hypertension (2015) found that at maximum approved doses, azilsartan 80 mg lowered 24-hour ambulatory systolic pressure by approximately 4.2 mmHg more than losartan 100 mg, and olmesartan 40 mg lowered it by roughly 2.9 mmHg more 6.

These numbers matter clinically. A 2-mmHg sustained systolic reduction translates to roughly a 7% lower stroke risk and a 5% lower coronary event risk 7. For a patient sitting at 142/88 on losartan 100 mg with a target of <130/80, switching to olmesartan 40 mg or azilsartan 80 mg can close the gap without adding a second drug.

Protocol for switching to a stronger ARB:

1. Confirm the patient is on losartan 100 mg (maximum dose) and still above target.
2. Select the equivalent or slightly higher starting dose of the new ARB using the table above.
3. Discontinue losartan and start the new ARB the next day. No overlap or washout is needed.
4. Recheck office blood pressure in 2 to 4 weeks.
5. Recheck serum creatinine and potassium in 1 to 2 weeks.
6. Titrate the new ARB upward if blood pressure remains above goal and the agent has a higher maximum (e.g., candesartan can go to 32 mg).

Switching From an ACE Inhibitor to Losartan

ACE inhibitors (lisinopril, enalapril, ramipril) and ARBs both target the renin-angiotensin system but at different points. ACE inhibitors block the conversion of angiotensin I to angiotensin II; ARBs block angiotensin II at the receptor. Because they are not the same mechanism, a direct same-day switch is acceptable, though some clinicians prefer a 24-hour gap to reduce the theoretical risk of additive hypotension 5.

The most common reason for this switch is ACE-inhibitor cough. Dry cough affects 5 to 35% of patients on ACE inhibitors (higher rates in women and patients of East Asian descent), and it typically resolves within 1 to 4 weeks of stopping the ACE inhibitor 8. ARBs cause cough at rates comparable to placebo.

The second common reason is angioedema. Patients with a history of ACE-inhibitor angioedema can be switched to an ARB, but this should be done with a monitored observation period. The cross-reactivity rate for angioedema between ACE inhibitors and ARBs is low (estimated at 2 to 8%), but the consequence is serious 9. The American Academy of Allergy, Asthma & Immunology recommends a 6-week washout from the ACE inhibitor before starting an ARB in this population, with the first dose given in a monitored clinical setting.

Approximate ACE inhibitor to losartan conversion:

| ACE Inhibitor | Mid-range Dose | Losartan Equivalent | |---------------|---------------|---------------------| | Lisinopril | 20 mg | 50 mg | | Enalapril | 10 mg twice daily | 50 mg once daily | | Ramipril | 5 mg | 50 mg | | Benazepril | 20 mg | 50 mg | | Perindopril | 4 mg | 50 mg |

These equivalencies are approximate and based on comparative blood-pressure-lowering data, not head-to-head bioequivalence trials. The ONTARGET trial (N=25,620) established that telmisartan 80 mg and ramipril 10 mg produced nearly identical cardiovascular outcomes, providing the strongest evidence of ACE-inhibitor-to-ARB equivalence for that specific pair 10.

Switching From Losartan to a Non-ARB Antihypertensive

Not every switch stays within the renin-angiotensin system. Patients may move from losartan to a calcium channel blocker (amlodipine, nifedipine), a thiazide-type diuretic (chlorthalidone, hydrochlorothiazide), or a beta-blocker. The LIFE trial (N=9,193) compared losartan-based therapy to atenolol-based therapy in hypertensive patients with left ventricular hypertrophy and found losartan superior, with a 13% reduction in the composite of cardiovascular death, myocardial infarction, and stroke (p=0.021) 11. That trial is the primary reason guidelines favor ARBs over beta-blockers as first-line therapy in uncomplicated hypertension.

When a patient must leave losartan for a different class (e.g., due to hyperkalemia, pregnancy planning, or intolerance), the switch depends on the new drug's onset:

• To amlodipine: Start amlodipine 5 mg the day after the last losartan dose. Full effect takes 7 to 10 days, so recheck at 2 weeks.
• To chlorthalidone: Start chlorthalidone 12.5 to 25 mg the next morning. Monitor sodium and potassium at 2 weeks.
• To a beta-blocker: Start at a low dose (metoprolol succinate 25 to 50 mg) the day after losartan discontinuation. Beta-blockers are no longer first-line for uncomplicated hypertension per the 2017 ACC/AHA guideline 5 but remain indicated for heart failure with reduced ejection fraction, post-MI, and rate control.

There is no rebound hypertension risk from stopping losartan abruptly. Unlike clonidine or short-acting beta-blockers, ARBs do not cause sympathetic rebound on discontinuation.

Why Losartan May Be Worth Keeping: The Uricosuric Advantage

Losartan has a pharmacologic property that no other ARB shares at a clinically meaningful level. It inhibits the URAT1 transporter in the proximal tubule, reducing serum uric acid by 0.3 to 0.7 mg/dL 12. For patients with coexisting hypertension and gout (or asymptomatic hyperuricemia above 8 mg/dL), this effect can be clinically relevant.

The LIFE trial included a prespecified analysis of uric acid changes. Losartan's uric acid reduction accounted for 29% of its stroke-risk benefit compared to atenolol, a finding that generated considerable interest in uric acid as a cardiovascular risk modulator 13.

Before switching a patient off losartan, check their uric acid level. If it is borderline elevated (6.5 to 7.5 mg/dL in men, 5.5 to 6.5 mg/dL in women), switching to another ARB may push it above the crystallization threshold. In this scenario, either maintain losartan (adding a second antihypertensive for blood pressure if needed) or plan for uric acid monitoring after the switch.

Monitoring After Any Switch

Every ARB switch, regardless of direction, warrants a standard monitoring protocol.

Week 1 to 2: Recheck serum creatinine and potassium. A creatinine rise of <30% from baseline is acceptable and expected with ARBs, as they reduce intraglomerular pressure. A rise above 30% should prompt investigation for renal artery stenosis or volume depletion 14.

Week 2 to 4: Recheck office blood pressure. If the patient uses home monitoring, have them log morning and evening readings for the first 2 weeks after the switch.

Month 3: Recheck creatinine, potassium, and blood pressure to confirm stability. Reassess whether the switch achieved its goal (better blood pressure control, cough resolution, uric acid management, or tolerability improvement).

Patients with heart failure or diabetic nephropathy require tighter monitoring. The RENAAL trial (N=1,513) established losartan 100 mg as renoprotective in type 2 diabetic nephropathy, reducing the risk of doubling serum creatinine by 25% vs. placebo 15. Switching these patients away from losartan should involve documented clinical reasoning and equivalent renoprotective dosing with the replacement ARB, ideally irbesartan 300 mg (supported by the IDNT trial 16) or valsartan 320 mg.

Special Populations: Adjustments Before Switching

Hepatic impairment: Losartan's conversion to EXP3174 depends on liver function. Patients with mild-to-moderate hepatic impairment should start losartan at 25 mg, and the FDA label recommends considering a lower starting dose of the replacement ARB as well 1. Telmisartan is also hepatically eliminated and should be avoided in moderate-to-severe liver disease. Olmesartan and azilsartan, which undergo less hepatic metabolism, may be better alternatives.

Renal impairment: No dose adjustment is required for losartan or most ARBs based on eGFR alone, but the risk of hyperkalemia rises as GFR falls below 30 mL/min/1.73 m². When switching ARBs in patients with CKD stage 4 or 5, start at the lower equivalent dose and recheck potassium within 5 to 7 days 14.

Pregnancy planning: All ARBs are contraindicated in pregnancy (FDA black-box warning for fetal renal injury and oligohydramnios in the second and third trimesters). Women planning conception should switch from losartan to a pregnancy-safe antihypertensive, with labetalol, nifedipine extended-release, or methyldopa as guideline-recommended options per ACOG Practice Bulletin 203 17.

Elderly patients (age ≥75): Start replacement ARBs at the lowest equivalent dose and titrate slowly. Orthostatic hypotension risk increases with switching, particularly if the patient also takes a diuretic or alpha-blocker. Check standing blood pressure at the follow-up visit.